The Combination of Periostin Overexpression and Microvascular Invasion Is Related to a Poor Prognosis for Hepatocellular Carcinoma.
- Author:
Se Young JANG
1
;
Soo Young PARK
;
Hye Won LEE
;
Yeon Kyung CHOI
;
Keun Gyu PARK
;
Ghil Suk YOON
;
Won Young TAK
;
Young Oh KWEON
;
Keun HUR
;
Won Kee LEE
Author Information
- Publication Type:Original Article
- Keywords: Periostin; Microvascular invasion; Hepatocellular carcinoma; Tissue microarray analysis; Prognosis
- MeSH: Carcinoma, Hepatocellular*; Extracellular Matrix; Humans; Immunohistochemistry; Prognosis*; Survival Rate; Tissue Array Analysis
- From:Gut and Liver 2016;10(6):948-954
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND/AIMS: Periostin is an extracellular matrix protein and is known to be related to the metastatic potential and prognosis of cancer. However, few studies have investigated the expression level of periostin and its association with prognoses in hepatocellular carcinoma. Therefore, we analyzed periostin overexpression in hepatocellular carcinoma and its implication for prognoses. METHODS: We evaluated 149 patients who underwent surgical resection between 2006 and 2010. Tissue microarrays were constructed from hepatocellular carcinoma tissue and adjacent nontumor tissue, and immunohistochemistry was performed. RESULTS: A high periostin level was observed more frequently in cases of multiple tumors (odds ratio [OR], 2.826; 95% confidence interval [CI], 1.224 to 6.527; p=0.013), positive microvascular invasion (OR, 2.974; 95% CI, 1.431 to 6.181; p=0.003), and advanced stage disease (OR, 3.032; 95% CI, 1.424 to 6.452; p=0.003). Patients with high periostin expression had significantly (p=0.002) lower overall survival rates than those with low periostin expression (90.3%, 66.1%, and 56.2% vs 97.7%, 85.1%, and 77.5% at 1, 3, and 5 years). CONCLUSIONS: We found that a combination of periostin overexpression and microvascular invasion in hepatocellular carcinoma was correlated with a poor prognosis and can be a good prognostic marker for hepatocellular carcinoma.
